TB-500 Quick Start
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4 (Tβ4), a naturally occurring actin-binding protein. It is studied in cell-migration, soft-tissue, muscle, and wound-healing models, and is frequently paired with BPC-157 in tissue-repair research planning. It is on the WADA Prohibited List.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
TB-500 Dosing Protocols
The injectable (subcutaneous) and nasal-spray formats are documented as two separate protocols. TB-500 is longer-acting than BPC-157, so research planning typically uses a twice-weekly loading phase followed by a weekly maintenance phase. Ranges are research-planning references, not personal dosing recommendations.
Injection — Subcutaneous
| Phase | Per dose | Frequency |
|---|---|---|
| Loading | 2–2.5 mg | 2× weekly |
| Maintenance | 2–2.5 mg | Weekly |
Nasal Spray
| Phase | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Loading | 2.5 mg | 13 sprays | 2× weekly |
| Maintenance | 2.5 mg | 13 sprays | Weekly |
TB-500 Reconstitution Guide
TB-500 ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays ship pre-mixed and ready to use.
Injection
| BAC | Conc. | 2.5 mg |
|---|---|---|
| 2 mL | 5 mg/mL | 0.5 mL · 50 u |
| 3 mL | 3.33 mg/mL | 0.75 mL · 75 u |
Units are U-100 syringe units.
Reconstitution steps
- Inspect the vial. Confirm label and intact powder.
- Wipe the stoppers. Alcohol swab on both vials.
- Draw BAC water. 2 mL into the injectable vial.
- Inject down the wall. Release water slowly down the inside wall, not onto the powder.
- Swirl, do not shake. Roll gently until clear.
- Refrigerate. Store at 2–8 °C; do not freeze.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
How TB-500 Works
TB-500 reproduces the actin-binding activity of Thymosin Beta-4. By regulating actin, a key cytoskeletal protein, it is reported in research to promote cell migration, support new blood-vessel formation (angiogenesis), and modulate inflammation — processes central to tissue repair. Its longer-acting profile, relative to BPC-157, is the basis for less frequent dosing.
Actin regulation
Binds G-actin and influences cytoskeletal dynamics underlying cell movement.
Cell migration
Reported to recruit repair cells into injured tissue.
Angiogenesis
Supports new blood-vessel formation in wound models.
Open question
Human efficacy and long-term safety are not established in controlled trials.
Who Should Avoid TB-500
Tested athletes
TB-500 / Tβ4 is on the WADA Prohibited List; use is an anti-doping rule violation.
Active or prior cancer
Pro-migratory, pro-angiogenic activity is a theoretical concern; discuss with a clinician.
Pregnancy & lactation
No human reproductive safety data.
Anyone seeking a treatment
TB-500 is a research compound, not a medical treatment.
TB-500 Side Effects & Safety
Injection-site reactions
Mild redness or lethargy after dosing are the most commonly reported short-term issues.
Theoretical proliferation risk
The same repair pathways could theoretically support unwanted cell growth; unresolved in humans.
Head-rush / fatigue
Transient effects are occasionally reported after larger doses.
Quality-control risk
Verify identity and purity against a Certificate of Analysis.
Timeline & What to Monitor
| Timeframe | Commonly tracked | Notes |
|---|---|---|
| Week 1–2 | Injection-site response, tolerability | Anti-doping violation applies immediately for tested athletes. |
| Week 2–4 | Functional / range-of-motion self-report | Loading phase window in most planning. |
| Week 4–6+ | Soft-tissue endpoints (animal models) | Transition to weekly maintenance; no human RCT covers this. |
Research Evidence Context
Thymosin β-4 research
Tβ4 has been studied in wound, cardiac, and corneal repair models, underpinning TB-500 interest.
Preclinical TB-500
Animal data report cell-migration and recovery effects in soft-tissue injury.
Human data
Limited; no large RCT establishes efficacy for musculoskeletal repair.
Open question
Planning ranges are community-derived, not validated clinical doses.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | More stable than reconstituted solution. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. |
| Appearance | Clear, colorless | Discard cloudy or particulate solutions. |
Mistakes & Troubleshooting
- Too many sprays feel impractical. The injection is the compact route for TB-500; the spray exists but needs multiple sprays per mg-range dose.
- Wrong BAC volume. Recalculate concentration; injection assumes 2 mL, spray assumes 5 mL.
- Missed dose. Resume the schedule; do not stack doses to compensate.
- Left out overnight. Treat reconstituted solution as compromised and discard.
TB-500 vs BPC-157
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Class | Thymosin β-4 fragment | 15-aa pentadecapeptide |
| Action | Actin / cell migration | Angiogenesis / VEGFR2 |
| Dosing cadence | 2× weekly → weekly | 1–2× daily |
| Combined | Paired in the "Wolverine" approach and available pre-blended in GLOW. | |
Frequently Asked Questions
What is TB-500?
A synthetic peptide based on the active region of Thymosin Beta-4, studied for cell migration and soft-tissue repair. It is banned by WADA.
How is the injection dosed vs the nasal spray?
Separate protocols. Injection commonly references 2–2.5 mg, twice weekly loading then weekly. Because TB-500 doses are in the milligram range, the spray uses a concentrated 5 mL fill (0.2 mg/spray) and needs ~13 sprays to match 2.5 mg — the injection is the more compact route.
How is TB-500 reconstituted?
For injection, 10 mg in 2 mL BAC water gives 5 mg/mL, so 2.5 mg = 0.5 mL = 50 units. The spray ships pre-mixed and delivers 0.2 mg per spray.
How does TB-500 compare to BPC-157?
They act through different mechanisms (actin/migration vs angiogenesis) and are often paired. See the GLOW blend, which combines both with GHK-Cu.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
References
- Goldstein AL, et al. Thymosin β4: actin-sequestering protein and tissue repair. Ann N Y Acad Sci (2012).
- Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol (1999).
- Bock-Marquette I, et al. Thymosin β4 and cardiac repair. Nature (2004).
- World Anti-Doping Agency. Prohibited List 2025.